J
Jonathan A. Ledermann
Researcher at University College London
Publications - 332
Citations - 28241
Jonathan A. Ledermann is an academic researcher from University College London. The author has contributed to research in topics: Ovarian cancer & Olaparib. The author has an hindex of 65, co-authored 300 publications receiving 21862 citations. Previous affiliations of Jonathan A. Ledermann include University College London Hospitals NHS Foundation Trust & University College Hospital.
Papers
More filters
Journal ArticleDOI
Positioning pemetrexed in the treatment of ovarian cancer
Radiofrequency ablation (RFA) combined with chemotherapy for unresectable colorectal liver metastases (CRC LM): Interim results of a randomised phase II study of the EORTC-NCRI CCSG-ALM Intergroup 40004 (CLOCC)
T.J.M. Ruers,F Van Coevorden,Jean-Pierre E. N. Pierie,IB Rinkes,C.J.A. Punt,Jonathan A. Ledermann,G. Poston,Wolf O. Bechstein,M.A. Lentz,Murielle Mauer,B. Nordlinger +10 more
Journal ArticleDOI
Genomic characterization of long-term responders to olaparib.
Stephanie Lheureux,Jonathan A. Ledermann,Sarah Runswick,Darren Hodgson,Kirsten Timms,Jerry S. Lanchbury,Stanley B. Kaye,Charlie Gourley,David D.L. Bowtell,Elise C. Kohn,Clare L. Scott,Ursula A. Matulonis,Tony Panzarella,Brian Dougherty,J. Carl Barrett,Zhongwu Lai,Mark J. O'Connor,Jane Robertson,Tony W. Ho,Amit M. Oza +19 more
TL;DR: This study characterised long (LT ≥ 2 years) and short-term (ST ≤ 3months) responders on olaparib maintenance and tested the association between presence and absence of any factor comparing ST vs LT.
Journal ArticleDOI
Evaluation of rucaparib in platinum-sensitive recurrent ovarian carcinoma (rOC) in patients (pts) with or without residual bulky disease at baseline in the ARIEL3 study.
Carol Aghajanian,Robert L. Coleman,Amit M. Oza,Domenica Lorusso,Ana Oaknin,Andrew Dean,Nicoletta Colombo,Johanne I Weberpals,Andrew R Clamp,Giovanni Scambia,Alexandra Leary,Robert W. Holloway,Peter C.C. Fong,Jeffrey C. Goh,David M. O'Malley,Susana Banerjee,Kenton Wride,T. Cameron,Jonathan A. Ledermann +18 more
TL;DR: Rucaparib significantly improved progression-free survival (PFS) vs placebo in all primary analysis groups in ARIEL3 and this data indicates that this drug should be considered as a ‘breakthrough therapy’.
Journal ArticleDOI
Exploratory analysis of the effect of maintenance rucaparib on postprogression outcomes in patients (pts) with platinum-sensitive recurrent ovarian carcinoma (OC) and updated safety data from the phase 3 study ARIEL3
Robert L. Coleman,Amit M. Oza,Domenica Lorusso,Carol Aghajanian,Ana Oaknin,Andrew Dean,Nicoletta Colombo,Johanne I Weberpals,Andrew R Clamp,Giovanni Scambia,Alexandra Leary,Robert W. Holloway,Margarita Amenedo,Peter C.C. Fong,Jeffrey C. Goh,David M. O'Malley,T. Cameron,Lara Maloney,Sandra Goble,Jonathan A. Ledermann +19 more
TL;DR: In ARIEL3, rucaparib maintenance treatment significantly improved progression-free survival (PFS) vs placebo in all predefined, nested cohorts: BRCA mutation; BRCa mutation + wild-t...